AB-PINACA

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. It is a potent agonist for the CB1 receptor and CB2 receptor with Ki values of 0.48 nM and 2.6 nM respectively.

Chemistry

AB-PINACA is a synthetic cannabinoid which is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication. It is a derivative of cannabinoids which are naturally occurring compounds found in the cannabis plant. The structure of AB-PINACA is closely related to that of other synthetic cannabinoids, with the main difference being the substitution of a valine amino acid for the terminal amide of the pentyl chain.

Pharmacology

AB-PINACA acts as a potent agonist for the CB1 receptor and CB2 receptor. The Ki values for binding central cannabinoid (CB1) and CB2 receptors are 0.48 nM and 2.6 nM, respectively, the values of which are similar to that of JWH-018, a synthetic cannabinoid found in several versions of the herbal mixture "Spice". In vivo, AB-PINACA has been found to have a potency of approximately 1.5 times that of THC, the primary psychoactive compound in cannabis.

Legal Status

In the United States, AB-PINACA is a Schedule I controlled substance. It is also illegal in many other countries, including Japan where it was first identified in synthetic cannabis products.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Cannabis (drug)

References

AB-PINACA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia